GLENMARK PHARMACEUTICALS
|
The Current P/S Ratio of GLENMARK PHARMACEUTICALS is 3.33.
| Share Price | ₹1,881.6 | Nov 20,2025 |
| Market Cap | ₹53,098.8 Cr | |
| Sales-TTM | ₹15,955.1 Cr | TTM-Consolidated Results |
| Price/Sales | 3.33x | Calculated as Market Cap/Sales |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PS (Price/Sales) ratio of GLENMARK PHARMACEUTICALS
P/S =
Market Capitalization
/
Sales
or, using per-share numbers:
P/S = Stock Price / Sales Per Share
Current Market Cap [ ₹53,098.8 Cr] as on Nov 20,2025
(/) Sales [ ₹15,955.1 Cr] based on TTM-Consolidated Results
(=) P/S Ratio [ 3.33x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay '3.33 times sales' to own 1 share of the company.
PS Multiples are one of the most widely used valuation multiple in the industry.
P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.
You may also explore Price to Earnings ratio or Price to Book ratio of GLENMARK PHARMACEUTICALS !
The chart below summarizes the trend in P/S Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PS (Price/Sales) ratio chart of GLENMARK PHARMACEUTICALS
PS Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 1.78x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 1.2x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 3.26x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2022 of 1.01x.
How does GLENMARK PHARMACEUTICALS 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Sales (Cr) | PS Ratio | Market Cap (Cr) |
|---|---|---|---|
| GLENMARK PHARMACEUTICALS | 15,955.1 | 3.33 | 53,098.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 54,964.0 | 7.76 | 426,566.0 |
| DIVIS LABORATORIES LTD | 10,029.0 | 17.11 | 171,594.0 |
| CIPLA LTD | 28,349.6 | 4.36 | 123,504.0 |
| TORRENT PHARMACEUTICALS LTD | 12,248.0 | 10.27 | 125,826.0 |
| DR REDDYS LABORATORIES LTD | 34,310.0 | 3.04 | 104,132.0 |
| MANKIND PHARMA LTD | 13,576.9 | 6.80 | 92,336.1 |
| ZYDUS LIFESCIENCES LTD | 24,493.9 | 3.81 | 93,338.3 |
| LUPIN LTD | 24,750.7 | 3.75 | 92,757.0 |
| AUROBINDO PHARMA LTD | 32,514.5 | 2.16 | 70,181.2 |
| ABBOTT INDIA LTD | 6,714.4 | 9.35 | 62,787.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs GLENMARK PHARMACEUTICALS 's P/S Ratio
| Top 10 Industry Peers | PS Ratio |
|---|---|
| Min industry PS | 2.16x |
| Max industry PS | 17.11x |
| Median industry PS | 4.36x |
| Average industry PS | 6.52x |
You may also like the below Video Courses